

Press release 2024-09-02

## Launch of Zeqmelit® Initiated – Now Available at Pharmacies

**AcuCort has previously announced that the market launch of Zeqmelit® would begin in early September. In line with this plan, Zeqmelit® is available at Swedish pharmacies starting today, Monday, September 2nd. The product will soon also be available at pharmacies in Norway and Finland.**

The launch is proceeding exactly as planned, and we have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®, and the product is now available at Swedish pharmacies. It will soon also be available at pharmacies in Norway and Finland, says AcuCort's CEO, Jonas Jönmark.

### **For further information:**

Jonas Jönmark, vd, AcuCort AB

Tel: +46 70 365 5400

Email: [jonas.jonmark@acucort.se](mailto:jonas.jonmark@acucort.se)

### **About AcuCort AB (publ)**

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit [www.acucort.se](http://www.acucort.se) for more information.